Isradipine improves endothelium-dependent vasodilation in normotensive coronary artery disease patients with hypercholesterolemia

Journal of Hypertension

Volumn 19, Issue 5, 2001, Pages 899-905

  Bracht, Christiane ^b   Yan, Xiao Wei ^b   Brunner LaRocca, Hans Peter ^b   Sütsch, Gabor ^b   Amann, Franz Wolfgang ^b   Kiowski, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

Acetylcholine; Endothelium derived factors; Hypercholesterolemia; Isradipine; L NMMA; Sodium nitroprusside

Indexed keywords

ACETYLCHOLINE; CALCIUM ANTAGONIST; CHOLESTEROL; DIHYDROPYRIDINE DERIVATIVE; HIGH DENSITY LIPOPROTEIN; ISRADIPINE; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; ENDOTHELIUM LESION; FEMALE; FOREARM BLOOD FLOW; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; PLETHYSMOGRAPH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPHYGMOMANOMETER; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

EID: 0035003782     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200105000-00010     Document Type: Article

References (36)

1. 1 Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med 1986; 314(8):488-500.
2. 2 Vane JR, Ȧnggard EE, Botting RM. Regulatory functions of the endothelium, N Engl J Med 1990; 323:27-36.
3. 3 Kiowski W, Linder L, Stoschitzky K, Pfisterer M, Burckhardt D, Burkart F, et al. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 1994; 90(1):27-34.
4. 4 Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990; 81(6): 1762-1767.
5. 5 Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992; 90(6):2548-2554.
6. 6 Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83(2):391-401.
7. 7 Stroes ES, Koomans HA, de BT, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346(8973):467-471.
8. 8 Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DJ, Lerman A. Long·term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101(9):948-954.
9. 9 Henry PD, Bentley Kl. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 1981; 68(5):1366-1369.
10. 10 Habib JB, Bossaller C, Wells S, Williams C, Morrisett JD, Henry PD. Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110. Circ Res 1986; 58(2):305-309.
11. 11 Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997; 30(6):1606-1612.
12. 12 Perticone F, Ceravolo R, Maio R, Ventura G, Iacopino S, Cuda G, et al. Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients. Cardiovasc Res 1999; 41(1):1299-306.
13. 13 Verhaar MC, Honing ML, van DT, Zwart M, Koomans HA, Kastelein JJ, et al. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res 1999; 42(3):752-760.
14. 14 Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89(6):2519-2524.
15. 15 Investigators SSSS. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934):1383-1389.
16. 16 Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, N Engl J Med 1995; 333(20):1301-1307.
17. 17 Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 1999; 35(1):60-66.
18. 2+ channel antagonists. Trends Pharmacol Sci 1992; 13(6):256-262.
19. 19 Zhang X, Hintze TH, Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97(6):576-580.
20. 20 Naruse M, Tanabe A, Seki T, Adachi C, Yoshimoto T, Mishina N, et al. Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats. J Hypertens 1999; 17(1):53-60.
21. 21 Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial Superoxide anion production. J Clin Invest 1993; 91(6): 2546-2551.
22. 22 Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am J Cardiol 1995; 75(6):75B-81B.
23. 23 Galle J, Ochslen M, Schollmeyer P, Wanner C. Oxidized lipoproteins inhibit endothelium-dependent vasodilation. Effects of pressure and high-density lipoprotein. Hypertension 1994; 23(5):556-564.
24. 24 Ting HH, Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997; 95(12): 2617-2622.
25. 25 Lupo E, Locher R, Weisser B, Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol. Biochem Biophys Res Commun 1994; 203(3):1803-1808.
26. 26 Lesnik P, Dachet C, Petit L, Moreau M, Griglio S, Brudi P, et al. Impact of a combination of a calcium antagonist and a beta-blocker on cell-and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells. Arterioscler Thromb Vasc Biol 1997; 17(5):979-988.
27. 27 Mak IT, Weglicki WB. Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 1990; 66(5):1449-1452.
28. 28 Kauder WF, Watts JA, Antioxidant properties of dihydropyridines in isolated rat hearts. Biochem Pharmacol 1996; 51(6):811-819.
29. 29 Bruning TA, Chang PC, Kemme MJ, Vermeij P, Pfaffendorf M, van Zwieten PA. Comparison of cholinergic vasodilator responses to acetylcholine and methacholine in the human forearm. Blood Press 1996; 5(6):333-341.
30. 30 Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26(5):1235-1241.
31. 31 Benzuly KH, Padgett RC, Kaul S, Piegors DJ, Armstrong ML, Heistad DD. Functional improvement precedes structural regression of atherosclerosis. Circulation 1994; 89(4):1810-1818.
32. 32 Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350(9080):757-764.
33. 33 Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group [see comments]. Lancet 1998; 351(9118):1755-1762.
34. 34 Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356(9227):366-372. [Published erratum appears in Lancet 2000; 356(9228):514]
35. 35 Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT), INTACT Group Investigators. Lancet 1990; 335(8698):1109-1113.
36. 36 Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, et al. A controlled clinical trial to assess the affect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82(6):1940-1953.